Impact of anthropometric parameters on outcomes in Asians with metabolic dysfunction‐associated fatty liver disease
Journal of Cachexia, Sarcopenia and Muscle · 2023-12 · 14 (6) · 2747-2756
DOI: 10.1002/jcsm.13351 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, online erschienen am 25.10.2023. Verfasst von Kyu Yeon Choi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, CHA Bundang Medical Center, CHA University, Seongnam, South Korea. Hauptthemen laut MEDLINE: Hand Strength, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
We examined the incidence and predictors of clinical outcomes in metabolic dysfunction‐associated fatty liver disease (MAFLD), focusing on anthropometric parameters.
Methods
Adult patients with MAFLD were identified in nationwide databases and a hospital cohort. Primary endpoints were atherosclerotic cardiovascular disease (ASCVD) and advanced fibrosis. Logistic and Cox regression analyses were used to analyse the association between anthropometric parameters and endpoints.
Results
In total, 4407 of 15 256 (28.9%) and 6274 of 25 784 subjects (24.3%) had MAFLD in the nationwide database; of these, 403 (9.2%) and 437 (7.0%) subjects were of lean/normal weight, respectively. Compared to the overweight/obese group, the lean/normal weight group had a significantly lower muscle mass (15.0 vs. 18.9 kg) and handgrip strength (31.9 vs. 35.1 kg) and had a higher ASCVD risk (9.0% vs. 6.3% and 15.9% vs. 8.5%; P s < 0.001). Sarcopenia (odds ratio [OR], 6.66; 95% confidence interval [CI], 1.79–24.80) and handgrip strength (OR, 0.92; 95% CI, 0.86–0.97; P s = 0.005) were associated with the ASCVD risk in the lean/normal weight group. In a hospital cohort ( n = 1363), the ASCVD risk was significantly higher in the lean/normal weight group than in the overweight/obese group (median follow‐up, 39.1 months). Muscle mass was inversely correlated with the ASCVD risk (hazard ratio [HR], 0.72; 95% CI, 0.56–0.94), while visceral adiposity was associated with advanced fibrosis (HR, 1.36; 95% CI, 1.10–1.69; P s < 0.05).
Conclusions
Muscle mass/strength was significantly associated with the ASCVD risk in patients with MAFLD. Visceral adiposity was an independent predictor of advanced fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, CHA Bundang Medical Center, CHA University, Seongnam, South Korea.
- Department of Gastroenterology, CHA Gumi Medical Center, CHA University, Gumi, South Korea.
- Department of Endocrinology and Metabolism, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, South Korea.
ORCID-Profile: Yeonjung Ha
Zitieren
APA
Choi, K. Y., Kim, T. Y., Chon, Y. E., Kim, M. N., Lee, J. H., Hwang, S. G., Lee, J., Kwak, M. K., Hong, E. G., Choi, Y. M., & Ha, Y. (2023). Impact of anthropometric parameters on outcomes in Asians with metabolic dysfunction‐associated fatty liver disease. Journal of Cachexia, Sarcopenia and Muscle, 14(6), 2747-2756. https://doi.org/10.1002/jcsm.13351
Vancouver
Choi KY, Kim TY, Chon YE, Kim MN, Lee JH, Hwang SG, et al. Impact of anthropometric parameters on outcomes in Asians with metabolic dysfunction‐associated fatty liver disease. Journal of Cachexia, Sarcopenia and Muscle. 2023;14(6):2747-2756. doi:10.1002/jcsm.13351
BibTeX
@article{Choi2023,
author = {Choi, Kyu Yeon and Kim, Tae Yeon and Chon, Young Eun and Kim, Mi Na and Lee, Joo Ho and Hwang, Seong Gyu and Lee, Jiwoo and Kwak, Mi Kyung and Hong, Eun-Gyoung and Choi, Yun Mi and Ha, Yeonjung},
title = {Impact of anthropometric parameters on outcomes in Asians with metabolic dysfunction‐associated fatty liver disease},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2023},
volume = {14},
number = {6},
pages = {2747--2756},
doi = {10.1002/jcsm.13351}
}
EUVIMED